Company intelligence / Profile preview

Lung Biotechnology PBC

Silver Spring, Maryland, United Stateslungbiotechnology.com ↗

Ownership: Private
Development stage: Other

Overview

Lung Biotechnology is developing therapies for pulmonary arterial hypertension and other fatal lung diseases. Its subsidiary Lung Bioengineering operates EVLP centers to evaluate and improve donated lungs for transplantation.

Therapeutic areas: PulmonologyCardiovascular
Modalities: Biotechnology therapiesorgan manufacturingex-vivo lung perfusion (EVLP)
Industry: Biotech

Drug pipeline

1 asset

bone marrow-derived mesenchymal stem cells (National Heart, Lung, and Blood Institute)

Unknown

Partnerships

XVIVO Perfusion

Beyond the preview

Go deeper on Lung Biotechnology PBC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lung Biotechnology PBC.